A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
Part of paid clinical trials in Charlotte, North Carolina.
- Sponsor
- Wake Forest University Health Sciences
- Study ID
- NCT06866964
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Germ Cell Tumor
- Testicular Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Low-dose ASA — DRUG81 mg by mouth daily for 26 weeks
Study Details
The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls
Key Dates
- Start date
- Aug 28, 2025
- Status verified
- Jan 2026
- Primary completion
- Aug 31, 2029
- Completion
- Jan 31, 2031
Study Design
- Enrollment
- 35 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- PREVENTION
Arms
- Experimental: Low-dose aspirin (acetylsalicylic acid [ASA])ASA has been shown to reduce risk of VTE. It will be self-administered, a fixed dose of ASA (81 mg) by mouth daily for 26 weeks.
Primary Outcome Measure
Venous thromboembolism (VTE)-free [ Time Frame: 26 weeks after initiation of standard chemotherapy ]
Central Contacts
- Margarita Dzhanumova980-515-5300
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Atrium Health Wake Forest Baptist Comprehensive Cancer Center | Charlotte | North Carolina | 28204 | Landon Brown, MD (PRINCIPAL_INVESTIGATOR) |
| Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157 | Michael McCormack, MD (PRINCIPAL_INVESTIGATOR) |
| Aurora St. Luke's Medical Center MOB | Milwaukee | Wisconsin | 53215 | Antony Ruggeri, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Charlotte, NC
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsPHASE3 · Recruiting · Children's Oncology Group · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer SurvivorsRecruiting · Duke University · Durham, North Carolina